Evaluating Blue Zones Demography in Response to Recent Critiques
January 6, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ifex
(United States) [Available]Synonyms :
ifosfamide
Class :
Class: anti cancer drugs (antineoplastic agents), Sub class: nitrogen mustards
Brand Name :
Ifex
(United States) [Available]Synonyms :
ifosfamide
Class :
Class: anti cancer drugs (antineoplastic agents), Sub class: nitrogen mustards
Dosage forms and strengths:
Injectable powdered form or solution:
Injectable solution:
Kit of powder with mesna solution
Administer dose of 1.2 g/m² daily through intravenous infusion over 30 minutes on day number 1 to 5 for every 3 to 4 weeks
Dosage forms and strengths:
Injectable powdered form or solution:
Injectable solution:
Kit of powder with mesna solution
influenza virus vaccine quadrivalent
ifosfamide decreases the effect of action of influenza virus by antagonism.
ifosfamide decreases the effect of action of measles vaccine by antagonism.
ifosfamide decreases the effect of action of rubella vaccine by antagonism.
ifosfamide decreases the effect of action of rotavirus vaccine by antagonism.
ifosfamide decreases the effect of action of smallpox vaccine by antagonism.
ifosfamide decreases the effect of action of varicella virus vaccine by antagonism.
ifosfamide decreases the effect of action of yellow fever vaccine by antagonism.
ifosfamide decreases the effect of action of zoster vaccine by antagonism.
ifosfamide through pharmacodynamic antagonism, reduces the impact of the live rotavirus oral vaccine on the body
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of nephrotoxicity and ototoxicity increases.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine fexinidazole will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine lonafarnib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of ifosfamide enzal
when both drugs combine abiraterone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amiodarone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atazanavir will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atogepant will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine axitinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine bexarotene will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bicalutamide will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bosentan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine brigatinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine butabarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine carbamazepine will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine cobicistat will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine conivaptan will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine dabrafenib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin lactobionate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin stearate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amobarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine armodafinil will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine belzutifan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
the effect of action increases by effecting enzyme CYP2B6 metabolism
when both drugs combine erythromycin acetate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
May increase the anti-coagulant action when combined
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
When ifosfamide is used together with ridaforolimus, this leads to enhanced concentration serum of ifosfamide
By synergism effects, the toxicity of the other drug increases.
when both drugs are combined, there may be an increased metabolism of ifosfamide
when combined with ifosfamide, the metabolism of thiotepa increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
increases cardiac distress risk
when both drugs are combined, there may be an increased risk or severity of adverse effects
may enhance the risk of immunosuppression and bone marrow suppression
the effect of isofamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors decrease the concentration of active metabolites of ifosfamide in serum
increases cardiac distress risk
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs combine ruxolitinib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the effect of both drug increases by synergism.
Actions and Spectrum:
Actions:
The liver enzymes break down Ifosfamide. They change its form. These new forms connect with DNA and other cell parts. The DNA strands link up. This process kills the cells.
Spectrum:
Ifosfamide fights against cancer. It belongs to anti-neoplastic medicines. Ifosfamide treats blood cancers effectively. Examples are lymphoma, leukemia, multiple myeloma. They start in bone marrow or immune cells. It also works for testicular, breast, ovarian, lung, pancreatic cancers. So, Ifosfamide treats many kinds of cancer.
Adverse drug reactions:
Frequency defined
0.5-0.5%
1.8-1.8%
Frequency not defined
Black Box Warning:
The medicine might cause problems. It can make blood counts low, leading to deadly infections. You must check blood counts carefully before and after taking it. Be on the lookout for bad side effects that harm the brain. Stop the medicine if you notice anything wrong. It can also damage your kidneys. But you can take mesna to help prevent bladder issues that cause bleeding.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy and Lactation:
Pregnancy:
Lactation:
Pregnancy Categories:
Pharmacology:
Ifosfamide works much like cyclophosphamide to stop cells from growing. After being activated in the liver, it disrupts DNA. This prevents DNA and protein production in cells, stopping their growth cycle. Ifosfamide does not target any specific phase; it acts on cells during their full life cycle. In addition to targeting cancer cells, ifosfamide weakens the immune system’s response.
Pharmacodynamics:
Ifosfamide treats cancer by relying on liver enzymes. The enzymes activate it to work against cancer cells. They change Ifosfamide into other forms like 4-hydroxyifosfamide. This form then becomes a strong cancer-fighting agent called isophosphoramide mustard. But, the process also creates acrolein – a harmful substance that can damage the bladder. Ifosfamide mainly attacks cancer by disrupting DNA in the cancer cells. It eventually destroys the cancer cells. While we know how it generally works, many details are still unclear.
Pharmacokinetics:
Absorption
The drug enters the body quickly.
Distribution
It spreads into the spinal fluid and breast milk. Its volume ranges between 0.64 and 0.72 L/kg from day 1 to 5.
Metabolism
The liver breaks down the drug in two ways. One way produces a harmful waste called chloroacetaldehyde. About half of the drug leaves the body within 7 to 15 hours.
Elimination and Excretion
It is mostly eliminated and excreted through urine. 70% to 86% of the broken-down drug is excreted this way. 12% to 18% leaves as the original drug unchanged. Most of the drug and its metabolites exit through urine. Elimination takes around 7 hours for low doses. For high doses, it takes up to 15 hours.
Administration:
Ifosfamide enters the body via a vein – intravenously (IV). Many factors influence how it’s given. Things like a patient’s overall health shape the dose, when it’s taken, and how long treatment lasts. Doctors and nurses decide based on each person’s situation.
Patient Information Leaflet
Ifosfamide is an IV cancer treatment. Used for testicular cancer. Side effects may include vomiting, diarrhea, nausea, sleepiness, and mouth sores. Tell your doctor if you have irregular heartbeats or seizures right away. Don’t let the medicine touch your skin. Drink lots of fluids during treatment. Pregnant or breastfeeding women can’t take ifosfamide. Men who could have children must use condoms during sex. Follow dosage schedule exactly. Ask pharmacist how to store the medicine properly.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
